However, in gastric cancer, sLAG-3 could positively regulate and enhance the anti-tumor immunity of CD8+T cells and secretion of IL-12 and IFN-γ, thereby improve the survival of patients (50). This evidence concerns the gene CD8A and gastric cancer.